Altered substrate specificity of drug-resistant human immunodeficiency virus type 1 protease

Journal of Virology

Volumn 76, Issue 3, 2002, Pages 1359-1368

  Dauber, Deborah S ^a   Ziermann, Rainer ^a   Parkin, Neil ^a   Maly, Dustin J ^a   Mahrus, Sami ^a   Harris, Jennifer L ^a   Ellman, Jon A ^a   Petropoulos, Christos ^a   Craik, Charles S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; PROLINE; PROTEINASE; VIRUS ENZYME;

ARTICLE; ENZYME ACTIVE SITE; ENZYME BINDING; ENZYME SPECIFICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; VIRUS CHARACTERIZATION; VIRUS GENOME; VIRUS RESISTANCE;

EID: 0036147360     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.76.3.1359-1368.2002     Document Type: Article

References (48)

1. Trans-dominant inhibitory human immunodeficiency virus type 1 protease monomers prevent protease activation and virion maturation
2. Synthesis of positional-scanning libraries of fluorogenic peptide substrates to define the extended substrate specificity of plasmin and thrombin
3. Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: Clinical significance and implications for resistance to protease inhibitors
4. Identification of efficiently cleaved substrates for HIV-1 protease using a phage display library and use in inhibitor development
5. Analysis of subsite preferences of HIV-1 proteinase using MA/CA junction peptides substituted at the P3-P1′ positions
6. Resistance to human immunodeficiency virus type 1 protease inhibitors
7. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor
8. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor
9. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir
10. HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteins
11. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors
12. Novel Gag-Pol frameshift site in human immunodeficiency virus type 1 variants resistant to protease inhibitors
13. Structural mechanisms of HIV drug resistance
14. Kinetic properties of saquinavir-resistant mutants of human immunodeficiency virus type 1 protease and their implications in drug resistance in vivo
15. Rapid and general profiling of protease specificity by using combinatorial fluorogenie substrate libraries
16. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors
17. Mixture-based synthetic combinatorial libraries
18. Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles
19. Mutations in HIV-1 gag cleavage sites and their association with protease mutations
20. Active human immunodeficiency virus protease is required for viral infectivity
21. Sub-site preferences of the aspartic proteinase from the human immunodeficiency virus, HIV-1
22. Alteration of substrate and inhibitor specificity of feline immunodeficiency virus protease
23. Expedient solid-phase synthesis of fluorogenic protease substrates using the 7-amino-4-carbamoylmethylcoumarin (ACC) fluorophore
24. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: Phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients
25. Mutational analysis of the substrate binding pocket of murine leukemia virus protease and comparison with human immunodeficiency virus proteases
26. Peptide libraries: Determination of relative reaction rates of protected amino acids in competitive couplings
27. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1
28. The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions
29. The regulation of sequential processing of HIV-1 Gag by the viral protease
30. Analysis of retroviral protease cleavage sites reveals two types of cleavage sites and the structural requirements of the P1 amino acid
31. Hydrolysis of synthetic chromogenic substrates by HIV-1 and HIV-2 proteinases
32. Sensitive, soluble chromogenic substrates for HIV-1 proteinase
33. Human immunodeficiency virus, type 1 protease substrate specificity is limited by interactions between substrate amino acids bound in adjacent enzyme subsites
34. Drug-resistant HIV-1 proteases identify enzyme residues important for substrate selection and catalytic rate
35. Defining the level of human immunodeficiency virus type 1 (HIV-1) protease activity required for HIV-1 particle maturation and infectivity
36. Regulation of autoproteolysis of the HIV-1 and HIV-2 proteases with engineered amino acid substitutions
37. Macromolecular inhibitors of HIV-1 protease. Characterization of designed heterodimers
38. On the active site of proteases. 3. Mapping the active site of papain; specific peptide inhibitors of papain
39. The 80's loop (residues 78 to 85) is important for the differential activity of retroviral proteases
40. A simple, continuous fluorometric assay for HIV protease
41. Identification of a loop outside the active site cavity of the human immunodeficiency virus proteases which confers inhibitor specificity
42. Comparison of the HIV-1 and HIV-2 proteinases using oligopeptide substrates representing cleavage sites in Gag and Gag-Pol polyproteins
43. Studies on the role of the S4 substrate binding site of HIV proteinases
44. Kinetic and modeling studies of S3-S3′ subsites of HIV proteinases
45. The gag precursor contains a specific HIV-1 protease cleavage site between the NC (P7) and P1 proteins
46. JE-2147: A dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1
47. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo
48. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites